For your patients’ severe
By preventing exacerbations
& by reducing daily OCS dose
NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.
†Real-world study: Prespecified interim analysis of a 2-year prospective, observational cohort study at 1 year (N=822). Primary objective (shown above): Post-exposure NUCALA 1.23 vs baseline 4.28 (71% reduction; rate ratio 0.29; 95% CI: 0.26, 0.32). Secondary objective (shown above): Daily median maintenance OCS dose in OCS-dependent patient subgroup (n=298). Post-exposure NUCALA at Weeks 53-56 (n=222) 2.5 mg/day vs baseline 10 mg/day. Results are descriptive. Study limitations: May not reflect final results. Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.2
§Dose assessments based on data captured from medical records or patient recall without documentation of asthma control.2
II4.5-year open-label study: Assessed safety, immunogenicity, and efficacy of NUCALA (N=347). Select secondary endpoint: Mean exacerbations/year: 0.68 (95% CI: 0.60, 0.78) with NUCALA + asthma controller in all patients; based on exacerbations reported from the time a patient enrolled until study withdrawal (median duration 3.8 years). Rate prior to study start was 1.74.2,4 Results are descriptive.
*Trial 2: 32-week placebo controlled study (N=576) Primary endpoint: Frequency of exacerbations. NUCALA+SOC 0.83/year, placebo+SOC 1.74/year, P<0.001.
‡Trial 3: 24-week placebo-controlled OCS dose reduction trial (N=135).
NUCALA is for the:
- add-on maintenance treatment of patients 6 years and older with severe eosinophilic asthma (SEA). NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.
- add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults 18 years and older with inadequate response to nasal corticosteroids.
- treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
- treatment of patients aged 12+ with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.
CI=confidence interval; ED=emergency department; IL=interleukin; MOA=mechanism of action; OCS=oral corticosteroid; SOC=standard of care.